Patents Assigned to Sanford-Burnham Medical Research Institute
-
Patent number: 8071378Abstract: We have identified ZNF206, a novel repressor of human embryonic stem cell (hESC) differentiation. Repressing extra-embryonic endoderm development preserves the pluripotent state of human embryonic stem cells, and, conversely downregulating expression of ZNF206 in hESCs causes them to upregulate the expression of genes associated with the extra-embryonic endodermal lineage, down-regulate genes associated with the pluripotent state, and may lead to the further emergence of genes associated with even more differentiated lineages and phenotypes.Type: GrantFiled: August 6, 2008Date of Patent: December 6, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Evan Yale Snyder, Rodolfo Gonzalez
-
Publication number: 20110293556Abstract: This invention relates to Applicant's discovery that Metabolic Syndrome , a cluster of disorders stemming from a resistance to insulin, contributes directly to dementia, particularly Alzheimer's disease. Applicant's invention includes a screening method to determine susceptibility and diagnosis of dementia based on the risk factors for Metabolic Syndrome. Applicant's invention further includes methods for the prevention or treatment of dementia and other neurological conditions based on (1) minimizing insulin resistance, thereby preventing excess biosynthesis of insulin; (2) modulating the activity of IDE such that insulin competes less efficiently with ?-amyloid protein for the TDE; and (3) blocking the consequences of NMDA receptor activation, such as by minimizing the generation of NO and other harmful free radicals.Type: ApplicationFiled: August 8, 2011Publication date: December 1, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: Stuart A. LIPTON, Daniel EINHORN
-
Publication number: 20110288002Abstract: The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate C. elegans (BAG-1, BAG-2) and the fission yeast S. pombe (BAG-1A, BAG-1B) and the nucleic acid molecules that encode them.Type: ApplicationFiled: July 11, 2011Publication date: November 24, 2011Applicant: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Shinichi Takayama
-
Publication number: 20110281356Abstract: Methods and small molecule compounds for stem cell differentiation are provided. One example of a class of compounds that may be used is represented by the compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.Type: ApplicationFiled: May 13, 2011Publication date: November 17, 2011Applicants: Human BioMolecular Research Institute, Sanford-Burnham Medical Research InstituteInventors: Mark Mercola, John Cashman, Marion Lanier, Erik Willems
-
Patent number: 8053553Abstract: Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes.Type: GrantFiled: May 5, 2008Date of Patent: November 8, 2011Assignees: Socpra Sciences Sante Et Humaines, Illumina, Inc., Sanford-Burnham Medical Research InstituteInventors: Alex Strongin, Michal Lebl, Robert Day
-
Patent number: 8048983Abstract: The present invention provides a conjugate which contains a therapeutic moiety linked to a homing molecule that selectively homes to tumor blood vessels and tumor cells and that specifically binds the receptor bound by peptide KDEPQRRSARLSAKPAPPKPEPKPKKAPAKK (SEQ ID NO: 9). Methods of directing a conjugate of the invention to tumor blood vessels and tumor cells and of using a conjugate to treat cancer also are provided.Type: GrantFiled: October 20, 2008Date of Patent: November 1, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Erkki Ruoslahti, Kimmo Porkka, Sven Christian
-
Publication number: 20110263514Abstract: Provided are compositions and methods for delivery of therapeutic agents, such as chemically stabilized antisense oligonucleotides useful in RNA silencing. The compositions include interfering nanoparticles (iNOPs) associated with one or more agents. Several functional iNOP derivatives are provided which allow for targeted delivery of agents to specific cell types as well as exhibiting reduced cellular toxicity.Type: ApplicationFiled: March 16, 2011Publication date: October 27, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventor: TARIQ M. RANA
-
Publication number: 20110257233Abstract: The disclosure provides new compounds and compositions thereof, and methods for treating or ameliorating a disorder relating to CDG-Ia. In particular, the disclosure provides benzoisothiazolone inhibitors of PMI, which have been synthesized and their ability to drive glycosylation has been demonstrated. The disclosure provides two synthetic routes for these compounds, including a new copper-catalyzed N-arylation reaction amenable to parallel derivitization. The disclosed compounds represent potent inhibitors of PMI, and their dose-dependent efficacy in cell-based models of glycosylation have been demonstrated. In addition, the disclosed compounds are selective over PMM and therefore, are useful in treating or ameliorating a disorder relating to CDG-Ia.Type: ApplicationFiled: March 18, 2011Publication date: October 20, 2011Applicant: Sanford-Burnham Medical Research InstituteInventors: Nicholas D. P. Cosford, Hudson H. Freeze, Russell Dahl, Yalda Bravo, Vandana Sharma, Mie Ichikawa
-
Patent number: 8034901Abstract: The invention provides Bcl-G polypeptides and encoding nucleic acids. Bcl-G polypeptides include Bcl-GL and Bcl-GS. The invention also provides mouse Bcl-G. The invention also provides vectors containing Bcl-G nucleic acids, host cells containing such vectors, Bcl-G anti-sense nucleic acids and related compositions. The invention additionally provides Bcl-G oligonucleotides that can be used to hybridize to or amplify a Bcl-G nucleic acid. Anti-Bcl-G specific antibodies are also provided. Further provided are kits containing Bcl-G nucleic acids or Bcl-G specific antibodies. Such kits and reagents can be used to diagnose cancer, monitor response to therapy, or predict the prognosis of a cancer patient. The invention additionally provides methods of modulating apoptosis using Bcl-G polypeptides, encoding nucleic acids, or compounds that modulate the activity or expression of Bcl-G polypeptides. The methods for modulating apoptosis can be used to treat diseases such as cancer.Type: GrantFiled: December 23, 2009Date of Patent: October 11, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Adam Godzik
-
Publication number: 20110229496Abstract: The present invention provides a method of inhibiting survival of T helper 1 (Th1) memory cells by contacting or administering a population of Th1 cells with an agent that inhibits CD44 receptor expression or activation. The invention further provides a method of stimulating memory Th1 cell survival comprising contacting or administering Th1 cells with an agent that increases CD44 receptor activation or expression in the cells. The invention additionally provides a method of screening for agents capable of modulating Th1 cell survival.Type: ApplicationFiled: March 18, 2011Publication date: September 22, 2011Applicant: Sanford-Burnham Medical Research InstituteInventor: Linda M. Bradley
-
Publication number: 20110230364Abstract: The invention provides a method of identifying an effective compound that modulates the binding of Humanin to Bax or Bid. The invention also provides a method of identifying an effective compound that modulates an activity of Bax or Bid. In addition, the invention provides a method of identifying a Humanin-like compound that binds to Bax or Bid or modulates an activity of Bax or Bid, or inhibits the apoptotic activity of Bax or Bid. The invention further provides an isolated polypeptide containing a mitochondrial-derived form of Humanin (SEQ ID NO:3) or a functional fragment thereof where the fragment contains the methionine at position 16 of SEQ ID NO:3.Type: ApplicationFiled: March 21, 2011Publication date: September 22, 2011Applicant: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Bin Guo
-
Patent number: 8017326Abstract: The present invention provides a method of identifying an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. The method is practiced by contacting a Bit1 polypeptide, or active fragment thereof, and an AES polypeptide, or active fragment thereof, with an agent under conditions that allow the Bit1 polypeptide or active fragment thereof to associate with the AES polypeptide or active fragment thereof; and detecting an altered association of the Bit1 polypeptide or active fragment thereof and the AES polypeptide or active fragment thereof, where an altered association indicates that the agent is an effective agent that alters the association of a Bit1 polypeptide with an AES polypeptide. Such an effective agent can modulate apoptosis and can be a useful therapeutic agent.Type: GrantFiled: June 6, 2008Date of Patent: September 13, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Yiwen Jan, Michelle Matter, Jih-Tung Pai, Erkki Ruoslahti
-
Publication number: 20110212070Abstract: The present invention provides a method of differentiating progenitor cells to produce a population containing protected neuronal cells. A method of the invention includes the steps of contacting the progenitor cells with a differentiating agent; and introducing into the progenitor cells a nucleic acid molecule encoding a MEF2 polypeptide or an active fragment thereof, thereby differentiating the progenitor cells to produce a population containing protected neuronal cells. In one embodiment, the MEF2 polypeptide is human MEF2C or an active fragment thereof.Type: ApplicationFiled: March 31, 2011Publication date: September 1, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: Stuart A. Lipton, Shu-ichi Okamoto
-
Publication number: 20110201780Abstract: In accordance with the present invention, there are provided novel Death Domain (DD), Death Effector Domain (DED) and NB-ARC domain proteins. The invention also provides nucleic acid molecules encoding DD, DED and NB-ARC domain proteins, vectors containing these nucleic acid molecules and host cells containing the vectors. The invention also provides antibodies that can specifically bind to invention DDs, DEDs or NB-ARC domains. Such DDs, DEDs and NB-ARC domains and/or anti-DD, anti-DED or anti-NB-ARC domain antibodies are useful for discovery of drugs that suppress infection, autoimmunity, inflammation, allergy, allograft rejection, sepsis, and other diseases.Type: ApplicationFiled: March 17, 2011Publication date: August 18, 2011Applicant: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTEInventors: John C. Reed, Adam Godzik, Krzysztof Pawlowski, Loredana Fiorentino, Sug Hyung Lee, Wilfried Roth, Frank Stenner-Liewen
-
Patent number: 7999069Abstract: The application is related to the identification of peptides that selectively bind to Eph receptors of the B class. Also disclosed are uses of such peptides in the treatment of a variety of diseases. Additionally, imaging tumors in patients is described by administrating labeled peptides to patients and then obtaining an image of the labeled peptides.Type: GrantFiled: August 28, 2009Date of Patent: August 16, 2011Assignee: Sanford-Burnham Medical Research InstituteInventors: Elena B. Pasquale, Mitchell Koolpe
-
Patent number: 7994282Abstract: The present invention provides NB-ARC and CARD-containing proteins (NACs), nucleic acid molecules encoding NACs and antibodies specific for at least one NAC. The invention further provides chimeric NAC proteins. The invention also provides screening assays for identifying an agent that can effectively alter the association of a NAC with a NAC-associated protein. The invention further provides methods of modulating apoptosis in a cell by introducing into the cell a nucleic acid molecule encoding a NAC or an antisense nucleotide sequence. The invention also provides a method of using a reagent that can specifically bind to a NAC to diagnose a pathology that is characterized by an increased or decreased level of apoptosis in a cell.Type: GrantFiled: October 17, 2007Date of Patent: August 9, 2011Assignee: Sanford Burnham Medical Research InstituteInventor: John C. Reed
-
Publication number: 20110189137Abstract: The present invention provides methods for generating induced pluripotent stem (iPS) cells having an increased efficiency of induction as compared with conventional methods. The method includes treating a somatic cell with a nuclear reprogramming factor in combination with an agent that alters microRNA levels or activity in the cell and/or a p21 inhibitor. The invention further provides iPS cells generated by such methods, as well as clinical and research uses for such iPS cells.Type: ApplicationFiled: November 10, 2010Publication date: August 4, 2011Applicant: Sanford-Burnham Medical Research InstituteInventor: Tariq M. Rana
-
Publication number: 20110189711Abstract: The invention provides isolated nucleic acid molecules encoding PAAD-domain containing polypeptides and functional fragments thereof, including fragments containing PAAD domains, NACHT domains and ARED domains, encoded polypeptides, and antibodies. Also provided are methods of identifying polypeptides and agents that associate with a PAAD-domain containing polypeptide or fragment thereof, or that alter an association of a PAAD domain-containing polypeptides. Further provided are methods of identifying agents that modulate PAAD domain-mediated inhibition of NF?B activity, or modulate an activity of a NACHT domain of a PAAD domain-containing polypeptide. Also provided are methods of modulating NF?B transcriptional activity in a cell, and methods of altering expression of a PAAD domain-containing polypeptide in a cell.Type: ApplicationFiled: November 9, 2010Publication date: August 4, 2011Applicant: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Adam Godzik
-
Publication number: 20110190168Abstract: A novel human member of the Bcl-2 family Bcl-B has been identified, which is Closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is Widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, BCl-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family.Type: ApplicationFiled: November 15, 2010Publication date: August 4, 2011Applicant: Sanford-Burnham Medical Research InstituteInventors: John C. Reed, Ning Ke, Adam Godzik
-
Patent number: RE42700Abstract: The present invention provides compounds that are inducers or inhibitors of apoptosis of apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.Type: GrantFiled: July 25, 2008Date of Patent: September 13, 2011Assignees: Sanford-Burnham Medical Research Institute, Oregon State University, SRI International, Molecular Medicine Research Institute, Department of Veterans Affairs, Wayne State UniversityInventors: Marcia Dawson, Joseph A. Fontana, Xiao-Kun Zhang, Mark Leid, Ling Jong, Peter D. Hobbs